Besides, inhibiting monocyte recruitment by blocking C-C motif chemokine ligand 24 (CCL24) or CCL2 may be an appealing novel therapy to limit fibrotic manifestations of SSc (23). This evidence concerns the gene CCL24 and systemic sclerosis.